This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Official Journal: CADE approves Reckitt Bernckiser,Bristol-Myers Squib's drug-supply deal

( March 15, 2013, 10:11 GMT | Official Statement) -- MLex Summary: Brazilian competition regulator CADE has approved Reckitt Bernckiser and Bristol - Myers Squib's drug-supply collaboration deal. The three-year agreement covers the sale, distribution and commercialization rights of some of Bristol-Myers' drugs for $438 million. The plans were notified on 5 March and were approved without any restrictions.Read the OJ statement in Portuguese below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login